BET bromodomain inhibitor

CAS No. 1505453-59-7

BET bromodomain inhibitor( MDK3597 | MDK-3597 | MDK 3597 | BET bromodomain inhibitor )

Catalog No. M12098 CAS No. 1505453-59-7

It is a BET bromodomain inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 50 In Stock
5MG 80 In Stock
10MG 132 In Stock
25MG 267 In Stock
50MG 462 In Stock
100MG 672 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BET bromodomain inhibitor
  • Note
    Research use only, not for human use.
  • Brief Description
    It is a BET bromodomain inhibitor.
  • Description
    It is a BET bromodomain inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MDK3597 | MDK-3597 | MDK 3597 | BET bromodomain inhibitor
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    BET bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1505453-59-7
  • Formula Weight
    400.26
  • Molecular Formula
    C20H15Cl2N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(N)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC(Cl)=CC=C3C4=C1ON=C4C
  • Chemical Name
    (S)-2-[8-Chloro-6-(4-chloro-phenyl)-1-methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Xiao Y, et al. Rheumatology (Oxford). 2015 Aug 3
molnova catalog
related products
  • Menin-MLL inhibitor ...

    Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).

  • ZM223

    ZM223 is a potent non-covalent inhibitor of NEDD8 activating enzyme (NAE).

  • Butyrolactone 3

    Butyrolactone 3 (MB-3) is a histone acetyltransferase Gcn5 inhibitor with a weak affinity for CBP.Butyrolactone 3 has antimicrobial activity and has been used in cancer, metabolic and neurological disorders.